We calculated the overall survival of non-metastatic, triple-negative breast cancer patients included in the METABRIC according to the ratio between the expression of CD8A and FOXP3 genes (CD8A/FOXP3 ratio). Here, FOXP3 is linked to triple-negative breast carcinoma.